Table 2.

Histologic changes associated with cyclophosphamide

Tissue	Diagnosis	Group	1	2	3	4	5	6	Control	Control
		Sacrifice day	2	2	5	5	19	19	19	19
		Virus	+	+	+	+	+	+	−	−
		CP-D	−	+	−	+	−	+	−	+
		Severity
Bone marrow, femur	Number examined		0	0	0	0	2	2	2	2
	No significant lesions						2	0	2	0
	Atrophy, hematopoietic	Minimal						1
		Mild						1		1
		Moderate
		Marked								1
Bone marrow, sternum	Number examined		2	2	2	2	2	2	2	2
	No significant lesions		2	2	2	0	2	0	2	0
	Atrophy, hematopoietic	Mild						2		1
		Moderate				2				1
	Hyperplasia, megakaryocytic	Mild
Lymph node, mandibular	Number examined		0	0	0	0	2	2	2	2
	No significant lesions						2	0	2	0
	Depletion, lymphoid	Mild						1		2
		Moderate						1
	Edema	Mild						2		2
		Moderate
	Histiocytosis, sinus	Mild						2		1
	Hemorrhage, acute	Mild								1
Lymph node, mesenteric	Number examined		0	0	0	0	2	1	1	2
	No significant lesions						2	0	1	0
	Depletion, lymphoid	Mild								2
		Moderate						1
	Hemorrhage, acute	Mild
	Histiocytosis, sinus	Moderate
	Edema	Mild								1
Ovary	Number examined		0	0	0	0	2	2	2	2
	No significant lesions						2	0	2	1
	Mineralization	Minimal						1
	Delayed development	Mild								1
		Moderate						2
Spleen	Number examined		0	0	0	0	1	2	2	1
	No significant lesions						1	0	1	0
	Depletion, lymphoid	Moderate						1
		Marked						1
Vagina	Number examined		0	0	0	0	2	2	2	2
	No significant lesions						2	1	2	1
	Vaginitis, necrotizing	Moderate								1
		Marked						1